Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced that it has initiated the Phase 1b portion of the clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE